Analysts Estimate Colgate-Palmolive (CL) to Report a Decline in Earnings: What to Look Out for

Colgate-Palmolive (CL) is anticipated to report a 2.2% year-over-year decline in Q2 2025 earnings to $0.89 per share on flat revenues of $5.06 billion, with results expected August 1. Despite a recent slight upward revision in consensus EPS, the company's negative Zacks Earnings ESP of -0.11% and Zacks Rank #3 indicate it is not a strong candidate for an earnings beat, contrasting its four-quarter streak of exceeding estimates. Investors should closely watch actual results against these projections, as they will significantly influence near-term stock performance.

Analysis

Colgate-Palmolive (CL) is approaching its Q2 2025 earnings release on August 1 with a challenging consensus outlook. Wall Street anticipates a 2.2% year-over-year decline in earnings per share to $0.89, alongside flat revenues of $5.06 billion. While the company has a strong recent history of outperformance, having beaten consensus EPS estimates in the last four consecutive quarters, current proprietary indicators suggest a potential break in this trend. The company's Zacks Earnings ESP (Expected Surprise Prediction) is negative at -0.11%, indicating that the most recent analyst revisions are more bearish than the broader consensus. This negative ESP, combined with a neutral Zacks Rank #3 (Hold), makes it difficult to conclusively predict an earnings beat. This contrasts with a slight 0.22% upward revision in the consensus estimate over the last 30 days, highlighting that the bearish turn in sentiment is a very recent development. The situation reflects a broader trend, as industry peer Clorox (CLX) also displays a negative ESP and a more bearish Zacks Rank of #4 (Sell), suggesting potential headwinds within the consumer staples sector.

Key Decisions for Investors

• Given the conflicting data of a strong surprise history versus a negative Earnings ESP of -0.11%, investors should exercise caution and avoid initiating new long positions based solely on past performance ahead of the report.
• The key focus for the August 1 release will be whether actual results can defy the recent bearish analyst revisions; a miss on either the expected $0.89 EPS or $5.06 billion revenue could lead to a negative stock reaction.
• For investors with existing positions, it may be prudent to review exposure and consider hedging strategies to mitigate potential downside risk if the company fails to meet or beat expectations.
• Pay close attention to management's commentary on business conditions and forward guidance, as this will likely be more influential for the stock's sustained direction than the initial reaction to the headline numbers.